Case
Teaching Notes
Abstract
In December 2006, Pfizer announced the halt of the Torcetrapib clinical trial, a once very promising drug in the fight against coronary artery and heart disease. At the same time, Pfizer announced its initial plans of layoffs and cost reductions would be expedited as a result of the trials. With the loss of patent protections for a series of drugs including Lipitor, the cancellation of Bextra, and the black label warning on Celebrex tablets, how does Pfizer seek continued success while appeasing shareholders?
This case was prepared for inclusion in Sage Business Cases primarily as a basis for classroom discussion or self-study, and is not meant to illustrate either effective or ineffective management styles. Nothing herein shall be deemed to be an endorsement of any kind. This case is for scholarly, educational, or personal use only within your university, and cannot be forwarded outside the university or used for other commercial purposes.
2025 Sage Publications, Inc. All Rights Reserved
